http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
다발성 골수종에 대한 Vincristine , Melphalan 및 Prednisone ( VMP ) 복합화학요법의 치료 효과
김태유(Tae You Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),김효진(Hyo Jin Kim) 대한내과학회 1993 대한내과학회지 Vol.45 No.1
Background: The combination of melphalan and prednisone has been the standard therapy for multiple myeloma. However, owing to the emergence of the drug resistance, essentially most patients have relapse or progrssion during chemotherapy. Vincristine was reported to be albe to prevent the development of the resistance to melphalan. Methods: Sixty two patients with multiple myeloma were treated with a combination chemotherapy of vincristine, melphalan and prednisone (VMF). The regimen consists of vincristine 0.03 mg/kg i.v. (day 1), melphalan 0,1 mg/kg p.o. (day 1-7) and prednisone 1mg/kg p.o. (day 1-7), which was repeated every four weeks. Results: Among 51 evaluable patients, 29 patients (56%) achieved objective responses. The median duration of response was 15 months. The median time to progression of overall patients was 11 months. The factors influencing response were age (p<0.04) and performance status (p<0.03). The overall median surivival was 36 months. The single most important factor associated with prolonged survival was the responsiveness to remission induction chemotherapy (p<0.001). Leukopenia was observed in 42% and thrombocytopenia in 2%. Neurotoxicity due to vincristine was found in 5.2% of the patients. Conclusions: The VMP regimen was associated with relatively high response rate and well tolerted, producing only mild bone marrow suppression and neuratoxicity. This result shows that VMP combination chemotherapy is an effective treatment regimen for multiple myeloma.
Aggressive 비호즈킨 림프종의 예후인자 분석과 고위험군 환자 선별을 위한 International Prognostic Index Model
김경태(Kyung Tae Kim),김태유(Tae You Kim),임영혁(Young Hyuck Im),강윤구(Yoon Koo Kang),이창희(Chang Hee Lee),곽영임(Young Im Kwak),류백렬(Baek Yeol Ryoo),성주병(Ju Byeung Sung),이영우(Young Wo Lee),장은정(Eun Jung Jang),김재학(Jae Ha 대한내과학회 1997 대한내과학회지 Vol.53 No.3
Objective: Although the therapeutic outcome of aggressive non-Hodgkin's lymphoma (NHL) has been considerably improved by the introduction of combination chemotherapy, many patients still fail to achieve complete response(CR) and/or long-term survival. Because the outcome appears to depend on certain prognostic factors, long term prognosis can be predicted by identification of risk group. And also, the patients in high risk group may benefit from new therapeutic modality. In 1993, the international prognostic index model for aggressive NHL as developed far the purpose of predicting outcome and designing of therapeutic trial. Thus, analysis of prognostic factors was performed to identify independent factors for the end points of CR, overall survival, and disease-free survival. Methods : From 1989 to 1994, total 340 patients were treated with combination chemotherapy and/or radiotherapy for NHL in Korea Cancer Center Hospital. Among 340, informations on eleven prognostic factors(sex, age, performance status, Ann Arbor stage, serum LDH level, tumor size, number of extranodal disease sites, bone marrow involvement, presence of B symptom, sex, time to CR, and histologic grade) were avaliable for 273 patients. Among these, 221 patients with aggressive NHL(NCI clinical schema) were eligible for the prognostic factor analysis for the response and survival. Also, 186 patients were eligible to determine whether International Prognostic Index Model could be applicable for Korean NHL. Results: One hundred fifty patients(68%, 95% CI 62-74%) achieved a complete remission, 43 patients (20%) a partial remission. With a median follow-up of 3,5 years, overall 3 year survival rate was 6396, and 3 year DFS for the 150 CRs was 72%. In a univariate analysis for the CR and survival, Ann Arbor stage, number of extranadal disease, performance status, presence of B symptoms, presence of BM involvement, serum LDH level and histologic grade were found to be statistically significant prognostic factors. Among them, by multivariate analysis, number of extranodal disease(RR 0.2, 95% CI 0.1-0.7), B Symptoms (RR 0.4, 95% CI 0.2-0.9), and histologic grade(RR 0.2, 95% CI 0.08-0.7) showed to be independent adverse prognostic factors for CR. For disease-free survival, Ann Arbor stage(RR 2.6, 95% CI 1.1-6.4) was independent risk factor. For overall survival, number of extranodal involvement(RR 2, 95% CI 1.3-4) and histologic grade(RR 2, 95% CI 1.2-3.7) were independently significant prognostic factors. With these 2 independent prognostic factors for survival, we could establish a prognastic index model which could separate the high risk patients. However, the usefulness of this model should be confirmed in a larger patient population. The dose intensity of cyclophosphamide, during initial 3 months of treatment, was significantly associated with CR rate and overall survival(p=0.01 & 0.03, respectively). When International Prognostic Index Model was applied to our patients, patients in the lower risk groups had significantly better outcome than patients in the higher risk groups(3 year survival and RR: 77% & 1 for low risk group, 61% & 1.9 for low-intermediate risk group, 50% & 2.2 for high-intermediate risk group, and 25% & 6 for high risk group). Conclusion: In this study, we confirmed that features other than the Ann Arbor stage were independently associated with CR and survival, and the International Prognostic Index Model would be an useful tool for the selection of high-risk patients who could be benefited from more aggressive chemotherapy.
치료의 전력이 없는 다발성 골수종에 대한 Vincristine , Doxorubicin 및 Dexamethasone ( VAD ) 복합화학요법의 효과
김성환(Seong Whan Kim),류백렬(Baek Yeol Ryoo),김태유(Tae You Kim),임영혁(Young Hyuck Im),박연희(Yeon Hee Park),김봉석(Bong Seog Kim),최병국(Byung Kook Choi),김경현(Kyung Hyun Kim),강윤구(Yoon Koo Kang) 대한내과학회 1999 대한내과학회지 Vol.56 No.1
Objective : The combination of vincristine and doxorubicin by continuous infusion was reported to reduce tumor mass more rapidly than standard regimens, which maybe a result of effect on more slowly proliferating plasma cells. We conducted a phase II study to determine the activity and safety of VAD (vincristine, doxorubicin, dexamethasone) chemotherapy, in which vincristine and doxorubicin are administered as a continuous infusion, for previously untreated multiple myeloma. Methods : VAD chemotherapy (vincristine 0.4 mg/day 24 hour-continuous infusion, days 1∼4; doxorubicin 9 mg/m2/day 24 hour-continuous infusion, days 1∼4; dexamethasone 40 mg/day p.o. days 1∼4) was given to eligible patients every 4 weeks and we assessed response and toxicity of the regimen. Results : Between January 1991 and March 1997, total 25 patients entered this trial and 22 were evaluable. The complete response rate was 14%(3/22) and overall response rate was 59%(13/22, 95% C.I.: 38∼80%). The time to response was 1.0∼6.8(median 2.9) months. Progression free survival was 2∼39+(median 11.5) months and the overall survival was 3+∼42+(median 19.7) months. Toxicities of VAD regimen were leukopenia, infection, stomatitis and neurotoxicity, but there was no treatment-related death. Conclusion : VAD chemotherapy was tolerable, but not more active than the alkylating agent-based chemotherapy as a front-line treatment for the patients with multiple myeloma. But, because of its rapid response and relatively mild myelotoxicity, it could play a role for advanced or highly complicated disease and for remission induction before consolidation with high-dose chemotherapy.
Klinefelter 증후군에 병발된 원발성 종격동 생식세포종
김용조 ( Yong Jo Kim ),권교선 ( Gyo Seon Kwun ),이영우 ( Young Wo Lee ),김경태 ( Kyung Tae Kim ),박연희 ( Yeon Hee Park ),류백렬 ( Baek Yeol Ryoo ),김태유 ( Tae You Kim ),임영혁 ( Young Hyuck Im ),이춘택 ( Choon Taek Lee ),강윤구 대한결핵 및 호흡기학회 1996 Tuberculosis and Respiratory Diseases Vol.43 No.6
간이식 후 발생한 간세포암의 폐 전이에 대한 종양절제술의 역할
김현수(Hyun Soo Kim),서경석(Kyung-Suk Suh),전영민(Young-Min Jun),김태훈(Teahoon Kim),신우영(Woo Young Shin),이남준(Nam-Joon Yi),한국남(Kook Nam Han),김영태(Young Tae Kim),김태유(Tae-You Kim),이건욱(Kuhn Uk Lee) 한국간담췌외과학회 2009 한국간담췌외과학회지 Vol.13 No.4
Purpose: Liver transplantation (LT) has been advocated as a good management option for patients with hepatocellular carcinoma (HCC). The rate of HCC recurrence after LT is about 20%. Although the median survival time of patients with HCC recurrence is 7∼9 months, the role of surgical treatment for metastatic tumors has been reported on. In this study, we evaluated the role of metastasectomy for treating patients with pulmonary metastasis from HCC after LT. Methods: We retrospectively analyzed 10 patients with pulmonary metastasis after LT and who were treated between April 2005 and October 2007. The underlying liver disease was cirrhosis caused by chronic viral hepatitis. The surveillance protocol for HCC recurrence was as follows: assessing the serum alpha-fetoprotein level every 1 month, chest and abdomen-pelvic computed tomography every 3 months and a bone scan every 1 year or when bone metastasis was suspected. The patients with less than 3 metastatic lesions were recommended to undergo metastasectomy (Group S, n=6) and the patients with more 4 lesions were recommended nonsurgical management, including chemotherapy (Group N, n=4). Results: All the metastatic lesions were detected on the protocol chest CT scans. The median recurrence time was 7.4 months (0.8∼18.2) after LT; this was 11.0 (4.8∼18.2) months for Group S and 2.0 (0.8∼3.3) months for Group N. One patient had a single lesion and the others had multiple lesions on multilobes. The median survival times of Group S were 29.3 (18.5∼41.3) months after pulmonary metastasis and 40.3 (23.3∼48.0) months after transplantation; 5 patients had no recorded evidence of their disease status. The median survival time of Group N was 4.3 (4.0∼6.3) months after metastasis and 6.2 (5.3∼7.1) months after transplantation; all the patients have since died. Conclusion: The survival outcome seemed to be good for the patients who underwent pulmonary metastasectomy for HCC, if it was detected earlier and it was resectable (≤3 lesions). However, further study is required for validating the survival benefit of pulmonary metastasectomy.
김동완 ( Dong Wan Kim ),류민희 ( Min Hee Ryu ),김태유 ( Tae You Kim ),허대석 ( Dae Seog Heo ),방영주 ( Yung Jue Bang ),박재갑 ( Jae Gahb Park ),김노경 ( Noe Kyeong Kim ) 대한내과학회 2003 대한내과학회지 Vol.64 No.3
Background : It is the aim of this study to find out the prognostic factors in Korean colorectal cancer patients Methods : The analysis was performed on 406 patients diagnosed as colorectal cancer between Jan, 1990 and Dec. 1992. Survival rate was calcula
비호지킨림프종 환자에서 항암화학요법중 발생한 카포시육종 1 예
서지영(Gee Young Suh),김태유(Tae You Kim),박영석(Young Suk Park),서창인(Chang In Suh),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),김철우(Chul Woo Kim) 대한내과학회 1992 대한내과학회지 Vol.43 No.1
Kaposi`s sarcoma is generally regarded as a rare vascular tumor affecting the skin and subcutaneous tissues, but capable of involving many viscera. Once it was a rare tumor primarily affecting the elderly of Jewish and Mediterranean ancestry. But with the advent of immunosuppressive therapy, the tumor was frequently found in patients receiving these therapy sometimes with deadly results. Also it became the focus of many peoples attention when it became known that it is associated with the acquired immune deficiency syndrome. We recently experienced a case of a 34-year-old patient with non-Hodgkin`s lymphoma who after receiving seven months of anti-cancer chemotherapy, developed reddish brown papules which were proven to be Kaposi`s 4rcoma pathologically and report the findings of his immunologic test results. This patients immunologic parameter tests showed that, NK cell activity which is one of the parameters of cell-mediated immunity was markedly reduced compared to normal controls. And also peripheral T4 lymphocyte count fell significantly in parallel with the aggarvation of Kaposi`s sarcoma. These findings suggest that depressed cell-mediated immunity maybe related to the development and aggravation of Kaposi`s sarcoma in this patient.